IMR Press / EJGO / Volume 26 / Issue 6 / pii/2005249

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Adjuvant chemotherapy with paclitaxel and carboplatin in non-endornetrioid carcinoma of the uterus

Show Less
1 Department of Clinical Therapeutics, Alexandra Hospital, Athens (Greece)
2 Department of Gynecology and Obstetrics, University of Athens, Alexandra Hospital, Athens (Greece)
3 Department of Pathology, Alexandra Hospital, Athens (Greece)
Eur. J. Gynaecol. Oncol. 2005, 26(6), 627–631;
Published: 10 December 2005

Purpose of investigation: Uterine papillary serous carcinoma (UPSC) and uterine clear cell carcinoma (UCCC) represent more aggressive tumors than the more common endometroid cancers, exhibiting a propensity for distant metastasis. The aim of this study was to investigate the activity and safety of paclitaxel/carboplatin chemotherapy as the only adjuvant treatment in patients with sur­gically resected UPSC and UCCC. Methods: Fifteen patients with Stage IB-IV UPSC or UCCC were treated with a mean of six courses of paclitaxel 175 mg/m3 plus carboplatin AUC 5 at three-week intervals, three to six weeks after undergoing surgery with curative intent. No patient had residual disease after surgery and none underwent pre- or post-chemotherapy irradiation. Results: With a median follow-up of 29.4 months, six patients (40%) relapsed and two (13%) died of disease. Mean time to recur­rence was 16.9 months. Recurrence rate per Stage was 17% for Stage IB/C, 57% for Stage IIIAJC and 50% for Stage IV. Projected 5-year overall survival and progression-free survival was 79.7% and 55.7%, respectively. All relapses were abdominopelvic whereas in one case pelvic recurrence was accompanied by lung metastasis. The most frequent grade 3-4 toxicity was neutropenia. Conclusion: Chemotherapy with paclitaxel plus carboplatin is feasible and possibly prevents distant metastasis when used as adju­vant in UPSC and UCCC.

Endometrial cancer
Uterine papillary serous carcinoma
Uterine clear cell carcinoma
Adjuvant chemotherapy
Back to top